Quantification of HER family receptors in breast cancer
TLDR
The current available methodologies to measure HER family receptors are presented and the clinical implications of target quantification are discussed.Abstract:
The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification.read more
Citations
More filters
Journal ArticleDOI
Targeted therapies in breast cancer: New challenges to fight against resistance.
Viviana Masoud,Gilles Pagès +1 more
TL;DR: The main scope of this review is to provide a thorough update of recent developments in the field and discuss future prospects for preventing resistance mechanisms in the quest to increase overall survival of patients suffering from the disease.
Journal ArticleDOI
Recent Advances in Sensing Applications of Graphene Assemblies and Their Composites
Tran Thanh Tung,J. Nine,Melinda Krebsz,Tibor Pasinszki,Campbell J. Coghlan,Diana N. H. Tran,Dusan Losic +6 more
TL;DR: In this paper, the authors present and discuss recent advances in synthesis strategies of assembled graphene-based superstructures of 1D, 2D, and 3D macroscopic shapes in the forms of fibers, thin films and foams/aerogels.
Journal ArticleDOI
Recent advances in engineered graphene and composites for detection of volatile organic compounds (VOCs) and non-invasive diseases diagnosis
TL;DR: In this article, a brief overview of recent progress in graphene-based sensors for the detection of volatile organic compounds (VOCs) and diagnosis of diseases via non-invasive analysis is presented.
Journal ArticleDOI
ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation.
James Monypenny,Hanna Milewicz,Fabian Flores-Borja,Gregory Weitsman,Anthony Cheung,Ruhe Chowdhury,Thomas Burgoyne,Appitha Arulappu,Katherine Lawler,Paul R. Barber,Paul R. Barber,Jose Miguel Vicencio,Melanie Keppler,Wahyu Wulaningsih,Sean M. Davidson,Franca Fraternali,Natalie Woodman,Mark Turmaine,Cheryl Gillett,Dafne Franz,Sergio A. Quezada,Clare E. Futter,Alex von Kriegsheim,Walter Kolch,Borivoj Vojnovic,Jeremy G. Carlton,Jeremy G. Carlton,Tony Ng,Tony Ng +28 more
TL;DR: The data suggest that ALIX modulates immunosuppression through regulation of PD-L1 and EGFR and may, therefore, present a diagnostic and therapeutic target for BLBC.
Journal ArticleDOI
Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer.
TL;DR: It is concluded that lncRNAs play important roles in the pathophysiology of this disease and may serve as putative therapeutic targets and may be instrumental for improving current breast cancer clinical practices.
References
More filters
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
Mass spectrometry-based proteomics
Ruedi Aebersold,Matthias Mann +1 more
TL;DR: The ability of mass spectrometry to identify and, increasingly, to precisely quantify thousands of proteins from complex samples can be expected to impact broadly on biology and medicine.
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal ArticleDOI
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
Related Papers (5)
The HER2 extracellular domain as a prognostic and predictive factor in breast cancer.
Raquel A. Nunes,Lyndsay Harris +1 more